[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346727-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346727-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","efficacy-of-immune-checkpoint-inhibitors-and-oncoviruses-in-solid-tumors","Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors","","Viral infections contribute to a substantial share of cancers worldwide, with virus-driven malignancies disproportionately affecting low- and middle-income settings while metabolic and nonviral causes dominate elsewhere. Immune checkpoint inhibitors (ICI) can enhance antitumor immunity, yet clinical responses in virus-associated tumors vary. This review examines how distinct oncogenic viruses contribute directly and indirectly to carcinogenesis in solid tumors, emphasizing how infection status may shape immunotherapy effectiveness across heterogeneous tumor microenvironments and immune profiles.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/efficacy-of-immune-checkpoint-inhibitors-and-oncoviruses-in-solid-tumors/346727/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/efficacy-of-immune-checkpoint-inhibitors-and-oncoviruses-in-solid-tumors/346727.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How much of cancer worldwide is linked to infections and which infections are most common?","Question",{"text":63,"@type":64},"Approximately 12% to 20% of cancer cases are estimated to be linked to infections, with the majority associated with chronic viral infections rather than bacteria or multicellular parasites.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why do clinical outcomes with immune checkpoint inhibitors in virus-associated tumors vary?",{"text":68,"@type":64},"Although virus-associated tumors often show “hot” immune profiles, outcomes with ICIs remain inconsistent, potentially reflecting variability in tumor microenvironments and immune responses.",{"name":70,"@type":61,"acceptedAnswer":71},"Which types of oncogenic viruses are discussed as causes of solid tumors?",{"text":72,"@type":64},"Seven oncogenic viruses in humans are recognized, including DNA viruses such as EBV, KSHV/HHV8, MCPyV, high-risk HPV, and HBV, along with RNA viruses described as having distinct life cycles.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346727,1790987242,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors  \nHiba Mechahougui1,2, Lna Royston3, Catia Vieira Gomes2,4, Laurent Kaiser3,5, Thibaud Koessler1,2, Timothe Olivier1,2, Nicolas Mach1,2, S. Intidhar Labidi-Galy1,2, Kaushal Parikh6, and Alfredo Addeo1,2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Viral infections are estimated to contribute to 12% to 20% of all cancers worldwide, with virus-driven malignancies disproportionately affecting low- and middle-income countries, whereas metabolic and nonviral factors predominate in highincome regions. Key oncogenic viruses that cause solid tumors include high-risk human papillomaviruses, Epstein–Barr virus, hepatitis B virus, hepatitis C virus, Kaposi sarcoma–associated herpesvirus, and Merkel cell polyomavirus. Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by boosting\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | immune responses against tumors. Although viral infection– associated tumors often exhibit “hot” immune profiles, clinical outcomes with ICIs remain inconsistent. Some studies report improved survival in virus-associated cancers, whereas others indicate no clear benefit, which might reflect high variability in tumor microenvironments and immune responses. In this review, we aim to explore the direct and indirect contribution of different viruses to carcinogenesis in solid tumors, with a particular focus on immunotherapy effectiveness based on infection status. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nApproximately 12% to 20% of cancer cases are estimated to be linked to infections (1–4) . Although a portion of these cancers are caused by bacteria or multicellular parasites, the wide majority is associated with chronic viral infections (5) . The relative burden of virus-related cancers varies with geography and health system capacity. In low- and middle-income countries, gaps in prevention and treatment amplify disease burden; for example, limited access to hepatitis C virus (HCV) direct-acting antivirals and suboptimal hepatitis B virus (HBV) vaccination sustain chronic liver disease and hepatocellular carcinoma (HCC; ref. 6) . In high-income countries, immunosuppressed subgroups, like solid-organ transplant recipients and people living with human immunodeficiency virus (HIV), experience markedly higher incidences of several virus-associated malignancies owing to impaired cancer immunosurveillance and greater viral persistence (7) . After transplantation, human papillomavirus (HPV)–related cancers occur in significant excess and risk increases with time on immunosuppression (8) . In the same setting, Kaposi sarcoma and Merkel cell carcinoma (MCC) are strongly immunosurveillance sensitive, with large risk elevationsin transplant cohorts (9) . Separately, at the population level in high-income countries, the increase in HPV-positive oropharyngeal c","cbCaioojFD67plXA","https://ap.wps.com/l/cbCaioojFD67plXA","pdf",2685153,16,"English","# Introduction\n## Viral contribution to cancer burden\n## Geography and health system differences\n## Immunosuppression and virus-associated malignancies","[{\"question\":\"How much of cancer worldwide is linked to infections and which infections are most common?\",\"answer\":\"Approximately 12% to 20% of cancer cases are estimated to be linked to infections, with the majority associated with chronic viral infections rather than bacteria or multicellular parasites.\"},{\"question\":\"Why do clinical outcomes with immune checkpoint inhibitors in virus-associated tumors vary?\",\"answer\":\"Although virus-associated tumors often show “hot” immune profiles, outcomes with ICIs remain inconsistent, potentially reflecting variability in tumor microenvironments and immune responses.\"},{\"question\":\"Which types of oncogenic viruses are discussed as causes of solid tumors?\",\"answer\":\"Seven oncogenic viruses in humans are recognized, including DNA viruses such as EBV, KSHV/HHV8, MCPyV, high-risk HPV, and HBV, along with RNA viruses described as having distinct life cycles.\"}]","Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors | PDF",1790062544,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/442fd23f369349e857ecadec451501ea.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc1443f9812874efc936fc764803dc85.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e32f4c67460b66665a3dcba12e95af57.webp",981,1312,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b643995f4888882879bf479d7541a86.webp",980,1311]